2722. Risk of Infectious Adverse Events of Venetoclax Therapy in the Treatment of Hematologic Malignancies: A Systematic Review and Bayesian Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Venetoclax is a small molecule inhibitor of BCL-2 used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia. Recent post-marketing studies on venetoclax suggested that it may predispose to opportunistic infections (OIs). We sought to systematically review the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Prosty, Connor, Katergi, Khaled, Nguyen, Alex, Luo, Owen, Sorin, Mark, Cherniak, Vladimir, Sebag, Michael, Demir, Koray, McDonald, Emily, Lee, Todd C, Cheng, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677214/
http://dx.doi.org/10.1093/ofid/ofad500.2333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677214/
http://dx.doi.org/10.1093/ofid/ofad500.2333

Ejemplares similares